Bayesian models for subgroup analysis in clinical trials.

Area of Science:

• Pharmaceutical drug development
• Clinical trial analysis
• Statistical modeling

Background:

• Subgroup analysis in drug development is crucial but controversial due to issues like low power and multiple testing.
• Classical hypothesis testing for subgroup effects faces limitations in pharmaceutical research.
• Investigating treatment interactions with clinical or demographic factors is key in drug development.

Purpose of the Study:

• To explore shrinkage estimation techniques as an alternative to hypothesis testing for exploratory post hoc subgroup analysis.
• To review existing shrinkage models and propose a general modeling strategy for effect estimate shrinkage.
• To apply these methods to a case study of seven clinical trials and two artificial datasets.

Main Methods:

• Utilizing hierarchical modeling within a Bayesian framework with freely available software.
• Applying various subgroup model structures incorporating shrinkage estimation techniques.
• Emphasizing Bayesian approaches for robust statistical inference in subgroup analysis.

Main Results:

• The case study revealed minimal evidence of subgroup effects, with consistent inferences across multiple models.
• Model diagnostic checks indicated robustness of the findings, suggesting reliable results.
• Structured shrinkage techniques performed well, even when data suggested limited subgroup effects.

Conclusions:

• Post hoc subgroup examination should be viewed as exploratory, informing future study designs.
• Bayesian shrinkage techniques show promise for subgroup analysis in drug development, aiding decision-making.
• The utility of subgroup analysis is contingent on the quality and quantity of available data.